Heparin versus 0.9% sodium chloride intermittent flushing for prevention of occlusion in central venous catheters in adults

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 10, 2014, Pages

  López Briz, Eduardo ^a   Ruiz Garcia, Vicente ^a   Cabello, Juan B ^b   Bort Marti, Sylvia ^c   Carbonell Sanchis, Rafael ^d   Burls, Amanda ^e  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

^d Hospital de Sagunt   (Spain)

^e CITY UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; SODIUM CHLORIDE; ANTICOAGULANT AGENT;

ADULT; BLEEDING; CARDIOVASCULAR MORTALITY; CATHETER OCCLUSION; CATHETER THROMBOSIS; DRUG EFFICACY; FOLLOW UP; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEPSIS; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; CENTRAL VENOUS CATHETER; CENTRAL VENOUS CATHETERIZATION; LAVAGE; META ANALYSIS; PROCEDURES; STATISTICS AND NUMERICAL DATA;

ADULT; ANTICOAGULANTS; CATHETER OBSTRUCTION; CATHETERIZATION, CENTRAL VENOUS; CENTRAL VENOUS CATHETERS; HEPARIN; HUMANS; SODIUM CHLORIDE; THERAPEUTIC IRRIGATION;

EID: 84921961561     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD008462.pub2     Document Type: Review

References (350)

1. Bowers L, Speroni KG, Jones L, Atherton M. Comparison of occlusion rates by flushing solutions for peripherally inserted central catheters with positive pressure Luer-activated devices. Journal of Infusion Nursing 2008;31(1):22-7.
2. Goossens GA, Jérôme M, Janssens C, Peetermans WE, Fieuws S, Moons P, et al. Comparing normal saline versus diluted heparin to lock non-valved totally implantable venous access devices in cancer patients: a randomised, non-inferiority, open trial. Annals of Oncology 2013;24(7):1892-9.
3. Kaneko Y, Iwano M, Yoshida H, Kosuge M, Ito S, Narita I, et al. Natural saline-flush is sufficient to maintain patency of immobilized-urokinase double-lumen catheter used to provide temporary blood access for hemodialysis. Blood Purification 2004;22(5):473-9.
4. Pumarola CF, Mercader RC, Plana MC, Bueno CC, Casellas SS, Vidal MF, et al.[Comparative study of maintenance of patency of triple lumen central venous catheter] [Estudio comparativo del mantenimiento de la permeabilidad de los cateteres venosos centrales de tres luces]. Enfermeria Intensiva 2007;18(1):25-35.
5. Rabe C, Gramann T, Sons X, Berna M, Gonzalez-Carmona MA, Klehr HU, et al. Keeping central venous lines open: a prospective comparison of heparin, vitamin C and sodium chloride sealing solutions in medical patients. Intensive Care Medicine 2002;28(8):1172-6.
6. Schallom ME, Prentice D, Sona C, Micek ST, Skrupky LP. Heparin or 0.9% sodium chloride flush to maintain central venous catheter patency: a randomized trial. Critical Care Medicine 2012;40(6):1820-6.
7. American Association of Critical-Care Nurses. Evaluation of the effects of heparinized and nonheparinized flush solutions on the patency of arterial pressure monitoring lines: the AACN Thunder Project. By the American Association of Critical-Care Nurses. American Journal of Critical Care 1993;2(1):3-15.
8. Abbas SA, Haloob IA, Taylor SL, Curry EM, King BB, van der Merwe WM, et al. Effect of antimicrobial locks for tunnelled hemodialysis catheters on bloodstream infection and bacterial resistance: a quality improvement report. American Journal of Kidney Diseases 2009;53(3):492-502.
9. AbdelkefiA, Othman TB, Kammoun L, Chelli M, Romdhane NB, Kriaa A, et al. Prevention of central venous line-related thrombosis by continuous infusion of low-dose unfractionated heparin, in patients with haemato-oncological disease. A randomized controlled trial. Thrombosis and Haemostasis 2004;92(3):654-61.
10. AbdelkefiA, Torjman L, Ladeb S, Othman TB, Achour W, Lakhal A, et al. Randomized trial of prevention of catheter-related bloodstream infection by continuous infusion of low-dose unfractionated heparin in patients with hematologic and oncologic disease. Journal of Clinical Oncology 2005;23(31):7864-70.
11. AbdelkefiA. Prevention of catheter-related bloodstream infection in patients with haemato-oncological disease. http://clinicaltrials.gov/ct2/show/NCT00207779?term=Prevention+of+Catheter-Related+Bloodstream+Infection+in+Patients+With+Haemato-Oncological+Disease&rank=2 (accessed 6 October 2014) 2005.
12. AbdelkefiA, Achour W, Othman TB, Ladeb S, Torjman L, Lakhal A, et al. Use of heparin-coated central venous lines to prevent catheter-related bloodstream infection. Journal of Supportive Oncology 2007;5(6):273-8.
13. AbdelkefiA, Chelli M, Achour W, Ben Romdhane N, Torjman L, Ladeb S, et al. Catheter related bloodstream infection in haematological patients: a prospective, randomized study comparing Heparin-coated with chlorhexidine and silver sulfadiazine impregnated central venous catheters. Blood 2008;112(11):Abstract 1174.
14. Agnelli G. Prevention of venous and arterial thromboembolism in cancer patients undergoing chemotherapy, with a low molecular weight heparin (nadroparin calcium). A randomized, placebo-controlled, double-blind, multicenter phase III study. http://clinicaltrials.gov/ct2/show/NCT00951574?term=Prevention+of+Venous+and+Arterial+Thromboembolism%2C+in+Cancer+Patients+Undergoing+Chemotherapy%2C+With+a+Low+Molecular+Weight+Heparin+%28Nadroparin+Calcium%29&rank=1 (accessed 6 October 2014) 2009.
15. Akyuz C, Kupeli S, Yagci-Kupeli B, Buyukpamukcu M. Prophylactic taurolidine use in central venous catheters of pediatric cancer patients: a prospective randomized study from single center. Pediatric Blood and Cancer 2010;55(5):949.
16. Alexander H. Heparin versus normal saline as a flush solution. International Journal for the Advancement of Science and Arts 2010;1(1):63-75.
17. Alpan G, Eyal F, Springer C, Glick B, Goder K, Armon J. Heparinization of alimentation solutions administered through peripheral veins in premature infants: a controlled study. Pediatrics 1984;74(3):375-8.
18. Andersen KM, Holland JS. Maintaining the patency of peripherally inserted central catheters with 10 units/cc heparin. Journal of Intravenous Nursing 1992;15(2):84-8.
19. Ankola PA, Atakent YS. Effect of adding heparin in very low concentration to the infusate to prolong the patency of umbilical artery catheters. American Journal of Perinatology 1993;10(3):229-32.
20. Anton N, Cox PN, Massicotte MP, Chait P, Yasui Y, Dinyari PM, et al. Heparin-bonded central venous catheters do not reduce thrombosis in infants with congenital heart disease: a blinded randomized, controlled trial. Pediatrics 2009;123(3):e453-8.
21. Appelgren P, Ransjo U, Bindslev L, Larm O. Does surface heparinisation reduce bacterial colonisation of central venous catheters?. The Lancet 1995;345(8942):130.
22. Appelgren P, Ransjo U, Bindslev L, Espersen F, Larm O. Surface heparinisation of central venous catheters reduces microbial colonization in vitro and in vivo: results from a prospective, randomized trial. Critical Care Medicine 1996;24(9):1482-9.
23. Aquino VM, Sandler ES, Mustafa MM, Steele JW, Buchanan GR. A prospective double-blind randomized trial of urokinase flushes to prevent bacteremia resulting from luminal colonization of subcutaneous central venous catheters. Journal of Pediatric Hematology/Oncology 2002;24(9):710-3.
24. Araujo C, Silva JP, Antunes P, Fernandes JM, Dias C, Pereira H, et al. A comparative study between two central veins for the introduction of totally implantable venous access devices in 1201 cancer patients. European Journal of Surgical Oncology 2008;34(2):222-6.
25. Arnts IJ, Heijnen JA, Wilbers HT, van der Wilt GJ, Groenewoud JMM, Liem KD. Effectiveness of heparin solution versus normal saline in maintaining patency of intravenous locks in neonates: a double blind randomized controlled study. Journal of Advanced Nursing 2011;67(12):2677-85.
26. Arone KMB, Garbin LM, Reis PED, Galvao CM, Silveira RCCP. Thrombotic obstruction related of central venous catheter in patients submitted to haematopoietic stem cell transplantation. Bone Marrow Transplantation 2012;47(Suppl 1):S489.
27. Arrants J, Willis ME, Stevens B, Gripkey L, Herman JA, Hernandez-Brooks L, et al. Reliability of an intravenous intermittent access port (saline lock) for obtaining blood samples for coagulation studies. American Journal of Critical Care 1999;8(5):344-8.
28. Ashton J, Gibson V, Summers S. Effects of heparin versus saline solution on intermittent infusion device irrigation. Heart and Lung 1990;19(6):608-12.
29. Aslam S, Trautner BW, Ramanathan V, Darouiche RO. Pilot trial of N-acetylcysteine and tigecycline as a catheter-lock solution for treatment of hemodialysis catheter-associated bacteremia. Infection Control and Hospital Epidemiology 2008;29(9):894-7.
30. Aslam S, Darouiche RO. Mechanical integrity of haemodialysis catheters after exposure to a novel catheter lock solution. Infection Control and Hospital Epidemiology 2010;31(11):1124-9.
31. Aslam S. Phase II trial of a novel catheter lock solution for adjunctive treatment of hemodialysis catheter-associated bacteremia. http://clinicaltrials.gov/ct2/show/NCT01483872?term=Use+of+a+Novel+Catheter+Lock+Solution+For+Treatment+of+Hemodialysis+Catheter+Infections&rank=1 (accessed 6 October 2014) 2011.
32. Bailey MJ. Reduction of catheter-associated sepsis in parenteral nutrition using low-dose intravenous heparin. British Medical Journal 1979;1(6179):1671-3.
33. Balduini C. Heparin in prophylaxis of peripheral venous catheters thrombosis: randomized clinical trial [Studio clinico randomizzato sull'utilizzo di eparina per la profilassi della tromboflebite da catetere venoso periferico]. http://clinicaltrials.gov/ct2/show/NCT01131754?term=Heparin+100U%2FL+for+Prevention+of+PVC+Complications&rank=1 (accessed 6 October 2014) 2010.
34. Baltrons Bosch A, Coll Vinyoles S, Font Senen C, Jubany López M, Plana Illa C, Sunyer García A. Estudio comparativo del sellado de catéteres con citrato trisódico o heparina sódica más gentamicina. Revista de la Sociedad Española de Enfermeria Nefrologica 2008;11(2):95-100.
35. Barrett PJ, Lester RL. Heparin versus saline flushing solutions in a small community hospital. Hospital Pharmacy 1990;25(2):115-8.
36. Barriga FJ, Varas M, Potin M, Sapunar F, Rojo H, Martinez A, et al. Efficacy of a vancomycin solution to prevent bacteremia associated with an indwelling central venous catheter in neutropenic and non-neutropenic cancer patients. Medical and Pediatric Oncology 1997;28(3):196-200.
37. Bayes B, Bonal J, Romero R. Sodium citrate for filling haemodialysis catheters. Nephrology Dialysis Transplantation 1999;14(10):2532-3.
38. Beecroft PC. Intravenous lock patency in children: dilute heparin versus saline. Journal of Paediatric Pharmacological Practice 1997;2(4):211-23.
39. Bennegard K, Curelaru I, Gustavsson B, Linder LE, Zachrisson BF. Material thrombogenicity in central venous catheterization. I. A comparison between uncoated and heparin-coated, long antebrachial, polyethylene catheters. Acta Anaesthesiologica Scandinavica 1982;26(2):112-20.
40. Bertoglio S, Solari N, Meszaros P, Vassallo F, Bonvento M, Pastorino S, et al. Efficacy of normal saline versus heparinized saline solution for locking catheters of totally implantable long-term central vascular access devices in adult cancer patients. Cancer Nursing 2012;35(4):E35-E42.
41. Bertolino G, Pitassi A, Tinelli C, Staniscia A, Guglielmana B, Scudeller L, et al. Intermittent flushing with heparin versus saline for maintenance of peripheral intravenous catheters in a medical department: a pragmatic cluster-randomized controlled study. Worldviews on Evidence-Based Nursing 2012;9(4):221-6.
42. Betjes MG, van Agteren M. Prevention of dialysis catheter-related sepsis with a citrate-taurolidine-containing lock solution. Nephrology, Dialysis, Transplantation 2004;19(6):1546-51.
43. Betremieux P, Odent S, Prigent JY, Dabadie A, Roussey M, Lefrancois C. Study of continuous infusion of low doses of heparin in the prevention of complications of catheter during the neonatal period [Etude de l'infusion continue de bas doses de l'heparine pour la prevention de les complications du catheter pendant le periode neonatal]. Revue de Pediatrie 1988;24(7):311-5.
44. Birch P, Ogden S, Hewson M. A randomised, controlled trial of heparin in total parenteral nutrition to prevent sepsis associated with neonatal long lines: the Heparin in Long Line Total Parenteral Nutrition (HILLTOP) trial. Archives of Disease in Childhood. Fetal and Neonatal Edition 2010;95(4):F252-7.
45. Bisseling TM, Willems MC, Versleijen MW, Hendriks JC, Vissers RK, Wanten GJ. Taurolidine lock is highly effective in preventing catheter-related bloodstream infections in patients on home parenteral nutrition: a heparin-controlled prospective trial. Clinical Nutrition 2010;29(4):464-8.
46. Bleyer AJ, Mason L, Russell G, Raad II, Sherertz RJ. A randomized, controlled trial of a new vascular catheter flush solution (minocycline-EDTA) in temporary hemodialysis access. Infection Control and Hospital Epidemiology 2005;26(6):520-4.
47. Bolgiano CS, Subramaniam PT, Montanari JM, Minick L. The effect of two concentrations of heparin on arterial catheter patency. Critical Care Nurse 1990;10(5):47-57.
48. Bookstaver PB, Williamson JC, Tucker BK, Raad II, Sherertz RJ. Activity of novel antibiotic lock solutions in a model against isolates of catheter-related bloodstream infections. Annals of Pharmacotherapy 2009;43(2):210-9.
49. Bossert E, Beecroft PC. Peripheral intravenous lock irrigation in children: current practice. Pediatric Nursing 1994;20(4):346-9, 355.
50. Bracho-Blanchet E, Cortes-Sauza J, Davila-Perez R, Lezama-del Valle P, Villalobos-Alfaro C, Nieto-Zermeno J. Usefulness of intravenous heparin to prevent thrombosis of central venous catheter in children. Cirugia y Cirujanos 2010;78(5):423-9.
51. Branger B, Reboul P, Prelipcean C, Noguera ME, Cariou S, Granolleras C, et al. Tunnelled internal jugular vein catheters with taurolidine lock: an acceptable challenge to arterio-venous fistula in 70 years old haemodialyzed patients: a prospective pilot study. Nephrologie & Therapeutique 2011;7(4):237-41.
52. Branson PK, McCoy RA, Phillips BA, Clifton GD. Efficacy of 1.4 percent sodium citrate in maintaining arterial catheter patency in patients in a medical ICU. Chest 1993;103(3):882-5.
53. Brismar B, Hardstedt C, Jacobson S, Kager L, Malmborg AS. Reduction of catheter-associated thrombosis in parenteral nutrition by intravenous heparin therapy. Archives of Surgery 1982;117(9):1196-9.
54. Broom JK, O'Shea S, Govindarajulu S, Playford EG, Hawley CM, Isbel NM, et al. Rationale and design of the HEALTHY-CATH trial: a randomised controlled trial of Heparin versus EthAnol Lock THerapY for the prevention of Catheter Associated infecTion in Haemodialysis patients. BMC Nephrology 2009;10:23.
55. Broom JK, Krishnasamy R, Hawley CM, Playford EG, Johnson DW. A randomised controlled trial of Heparin versus EthAnol Lock THerapy for the prevention of Catheter Associated infecTion in Haemodialysis patients - The HEALTHY-CATH trial. BMC Nephrology 2012;13:146.
56. Brown-Smith JK, Stoner MH, Barley ZA. Tunneled catheter thrombosis: factors related to incidence. Oncology Nursing Forum 1990;17(4):543-9.
57. Butt W, Shann F, McDonnell G, Hudson I. Effect of heparin concentration and infusion rate on the patency of arterial catheters. Critical Care Medicine 1987;15(3):230-2.
58. Buturovic J, Ponikvar R, Kandus A, Boh M, Klinkmann J, Ivanovich P. Filling hemodialysis catheters in the interdialytic period: heparin versus citrate versus polygeline: a prospective randomized study. Artificial Organs 1998;22(11):945-7.
59. Cabrita J, Catorze N, Teixeira S, Carreto J, Vieira V, Goncalves S, et al. Maintenance of arterial catheters with heparin. It is time to stop!. Intensive Care Medicine 2011;37(Suppl 1):S168.
60. Calderero Aragon V, De Gregorio Ariza MA, Pazo Cid R, Puertolas Hernandez T, Lostale Latorre F, Artal Cortes A, et al. Role of low molecular weight heparins in prophylaxis of thromboembolic events on oncological patients with indwelling central venous catheter [Heparinas de bajo peso molecular en la profilaxis de episodios tromboembólicos en pacientes con cáncer portadores de catéter venoso central]. Medicina Clinica 2009;133(10):365-70.
61. Campbell MA. A randomized controlled crossover trial of two different central venous catheter flushing schemes in pediatric hematology and oncology patients in Alberta, Canada. http://clinicaltrials.gov/ct2/show/NCT01343680?term=Trial+of+Two+Central+Venous+Catheter+%28CVC%29+Flushing+Schemes+in+Pediatric+Hematology+and+Oncology+Patients&rank=1 (accessed 6 October 2014) 2011.
62. Campos RP, do Nascimento MM, Chula DC, Riella MC. Minocycline-EDTA lock solution prevents catheter-related bacteremia in hemodialysis. Journal of the American Society of Nephrology: JASN 2011;22(10):1939-45.
63. Cardinal P, Allan J, Pham B, Hindmarsh T, Jones G, Delisle S. The effect of sodium citrate in arterial catheters on acid-base and electrolyte measurements. Critical Care Medicine 2000;28(5):1388-92.
64. Carrasco MN, Bueno A, De Las Cuevas C, Jimenez S, Salinas I, Sartorius A, et al. Evaluation of a triple-lumen central venous heparin-coated catheter versus a catheter coated with chlorhexidine and silver sulphadiazine in critically ill patients. Intensive Care Medicine 2004;30(4):633-8.
65. Carratala J, Niubo J, Fernandez-Sevilla A, Juve E, Castellsague X, Berlanga J, et al. Randomized, double-blind trial of an antibiotic-lock technique for prevention of gram-positive central venous catheter-related infection in neutropenic patients with cancer. Antimicrobial Agents and Chemotherapy 1999;43(9):2200-4.
66. Carrero Caballero MC, Valbuena Esteban B. Maintenance and care of intravascular catheters. The significance of heparinization [Mantenimiento y cuidado de catéteres intravasculares]. Revista Enfermeria 2012;35(6):47-50.
67. Casale KE, Horst MA, Anderson AS, Devereux RB. Lower concentration of heparinized flush solution is associated with a higher incidence of femoral sheath clot following diagnostic cardiac catheterization. Journal of the American College of Cardiology 2009;53(10 Suppl 1):A24.
68. Catorze N, Teixeira S, Cabrita J, Carreto J, Vieira V, Gonçalves S, et al. Maintenance of arterial catheters with heparin; should we continue?. Critical Care 2011;15(Suppl 1):P78.
69. Catton JA, Davies J, Dobbins BM, Wood JM, McMahon MJ, Burke D. The effect of heparin in peripheral intravenous nutrition via a fine-bore midline: a randomised double-blind controlled trial. Clinical Nutrition 2006;25(3):394-9.
70. Cesaro S, Tridello G, Cavaliere M, Magagna L, Gavin P, Cusinato R, et al. Prospective, randomized trial of two different modalities of flushing central venous catheters in pediatric patients with cancer. Journal of Clinical Oncology 2009;27(12):2059-65.
71. Chang GY, Lueder FL, DiMichele DM, Radkowski MA, McWilliams LJ, Jansen RD. Heparin and the risk of intraventricular hemorrhage in premature infants. Journal of Pediatrics 1997;131(3):362-6.
72. Cheronis JC. Multi-center, prospective, randomized, open-label, sponsor-blinded, active-control (heparin) clinical investigation to evaluate the safety and effectiveness of B-Lock™ as an antimicrobial catheter lock solution in dialysis patients with a central venous catheter. http://clinicaltrials.gov/ct2/show/NCT01989091?term=Antimicrobial+Lock+Solution+in+Dialysis+Patients+With+a+CVC&rank=1 (accessed 6 October 2014) 2013.
73. Chu KH, Cheung W, Chan W, Fung KS, Tang HL, Yim KF, et al. A single centre experience of using gentamicin/heparin lock solution in preventing dialysis catheter-related infection. Hemodialysis International 2009;13(3):372.
74. Clark TWI, David Jacobs D, Charles HW, Kovacs S, Aquino T, Erinjeri J, Benstein JA. Comparison of heparin-coated and conventional split-tip hemodialysis catheters. Cardiovascular and Interventional Radiology 2009;32(4):703-6.
75. Clifton GD, Branson P, Kelly HJ, Dotson LR, Record KE, Phillips BA, et al. Comparison of normal saline and heparin solutions for maintenance of arterial catheter patency. Heart and Lung 1991;20(2):115-8.
76. Coli L, Donati G, Cianciolo G, Raimondi C, Comai G, Panicali L, et al. Anticoagulation therapy for the prevention of hemodialysis tunneled cuffed catheters (TCC) thrombosis. Journal of Vascular Access 2006;7(3):118-22.
77. Conte GF, Aravena PC, Fardella PD, Araos DM, Alfaro JI, Flores CA, et al. Prophylaxis of venous thrombosis (VT) associated with central venous catheter (CVC) with low molecular weight heparin (LMWH) in hematologic malignancies [abstract]. Blood 2003; Vol. 102, issue 11:122b.
78. Coplon N. Prophylactic antimicrobial catheter lock in hemodialysis patients: a randomized controlled clinical trial. http://clinicaltrials.gov/ct2/show/NCT00571259?term=Prophylactic+Antimicrobial+Catheter+Lock&rank=1 (accessed 6 October 2014) 2007.
79. Corbett R, Ashby D, Edwards C, Prout V, Singh S, Bedi R, Duncan N. A randomised control trial of taurolidine-heparin-citrate line locks in prevention of recurrence of catheter related bacteraemia in haemodialysis patients. Nephrology Dialysis Transplantation 2013;28(Suppl 1):i19.
80. Cortes J. Prospective, randomized trial comparing heparin and minocycline-EDTA flush for the prevention of catheter-related infections and occlusions. http://clinicaltrials.gov/ct2/show/NCT00378781?term=Heparin+or+M-EDTA+in+Preventing+Catheter-Related+Infections+and+Blockages+in+Patients+at+High+Risk+for+a+Catheter-Related+Infection&rank=1 (accessed 6 October 2014) 2006.
81. Cottee S. Heparin lock practice in total parenteral nutrition. Professional Nurse 1995;11(1):25-6, 28-9.
82. Crews BE, Gnann KK, Rice MH, Kee CC. Effects of varying intervals between heparin flushes on pediatric catheter longevity. Pediatric Nursing 1997;23(1):87-91.
83. Daghistani D, Horn M, Rodriguez Z, Schoenike S, Toledano S. Prevention of indwelling central venous catheter sepsis. Medical and Pediatric Oncology 1996;26(6):405-8.
84. Danek GD, Noris EM. Pediatric i.v. catheters: efficacy of saline flush. Pediatric Nursing 1992;18(2):111-3.
85. Daniell HW. Heparin in the prevention of infusion phlebitis. A double-blind controlled study. JAMA 1973;226(11):12317-21.
86. Davanipur M, Pakfetrat M, Roozbeh J. Cloxacillin as an antibiotic lock solution for prevention of catheter-associated infection. Iranian Journal of Kidney Diseases 2011;5(5):328-31.
87. David RJ, Merten DF, Anderson JC, Gross S. Prevention of umbilical artery catheter clots with heparinized infusates. Developmental Pharmacology and Therapeutics 1981;2(2):117-26.
88. De Cicco M, Matovic M, Balestreri L, Steffan A, Pacenzia R, Malafronte M, et al. Early and short-term acenocumarine or dalteparin for the prevention of central vein catheter-related thrombosis in cancer patients: a randomized controlled study based on serial venographies. Annals of Oncology 2009;20(12):1936-42.
89. de la Torre Montero JC, Montealegre Sanz M. Heparinization versus salinization in short peripheral catheters for blood draws in clinical trials [Heparinización versus salinización en catéteres periféricos cortos para extracciones de sangre en ensayos clínicos]. Metas de Enfermeria 2012;15(7):15-8.
90. del Cotillo M, Grane N, Llavore M, Quintana S. Heparinized solution vs. saline solution in the maintenance of arterial catheters: a double blind randomized clinical trial. Intensive Care Medicine 2008;34(2):339-43.
91. del Pozo JL. Concentration and antibiotic activity in antibiotic lock solutions. http://clinicaltrials.gov/ct2/show/NCT01592032?term=Study+of+Concentration+and+Antimicrobial+Activity+of+Antibiotics+Used+for+Catheter-Related+Infections&rank=1 (accessed 6 October 2014) 2012.
92. de Neef M, Heijboer H, van Woensel JB, de Haan RJ. The efficacy of heparinization in prolonging patency of arterial and central venous catheters in children: a randomized double-blind trial. Pediatric Hematology and Oncology 2002;19(8):553-60.
93. Dias EF, Viana ACN, Lourdes Andraus MS, Pereira MS. [Use of intermittent intravenous device in pediatrics]. Revista Eletronica de Enfermagem 2000;2(2):1-12.
94. Dillon PW, Jones GR, Bagnall-Reeb HA, Buckley JD, Wiener ES, Haase GM, Children's Oncology Group. Prophylactic urokinase in the management of long-term venous access devices in children: a Children's Oncology Group study. Journal of Clinical Oncology 2004;22(13):2718-23.
95. Dogra GK, Herson H, Hutchison B, Irish AB, Heath CH, Golledge C, et al. Prevention of tunnelled hemodialysis catheter-related infections using catheter-restricted filling with gentamicin and citrate: a randomized controlled study. Journal of the American Society of Nephrology 2002;13(8):2133-9.
96. Donham JA, Denning V. Heparin vs. saline in maintaining patency, intermittent infusion devices: pilot study. Kansas Nurse 1987;62(11):6-7.
97. Dümichen MJ, Seeger K, Lode HN, Kühl JS, Ebell W, Degenhardt P. Randomized controlled trial of taurolidine citrate versus heparin as catheter lock solution in paediatric patients with haematological malignancies. The Journal of Hospital Infection 2012;80(4):304-9.
98. Duncan N, Singh S, Amao M, Brown W, Dalby E, Edwards C, et al. A single centre randomised control trial of sodium citrate versus Heparin line locks for cuffed central venous catheters [abstract no: F-PO539]. Journal of the American Society of Nephrology 2005; Vol. 16:451A.
99. Duncan N. A randomised controlled trial of taurolidine with heparin for prevention of recurrence of catheter related bacteraemia in haemodialysis patients. http://clinicaltrials.gov/ct2/show/NCT01243710?term=Taurolidine+in+Haemodialysis+Catheter+Related+Bacteraemia&rank=1 (accessed 6 October 2014).
100. Dünser MW, Mayr AJ, Hinterberger G, Flörl CL, Ulmer H, Schmid S, et al. Central venous catheter colonization in critically ill patients: a prospective, randomized, controlled study comparing standard with two antiseptic-impregnated catheters. Anesthesia and Analgesia 2005;101(6):1778-84.
101. Dupuis E, Duval X, Domic Q, Bonnal C, Lucet JC, Cerceau O, et al. Trisodium citrate 46.7% versus heparin catheter locks for tunneled central venous catheters: a single-center study. Nephrology Dialysis Transplantation 2012;27(Suppl 2):ii253.
102. Edstrom CS, McBride J, Theriaque D, Kao KJ, Christensen RD. Obtaining blood samples for anti-factor Xa quantification through umbilical artery catheters. Journal of Perinatology 2002;22(6):475-7.
103. Eloy R, Belleville J, Paul J, Pusineri C, Baguet J, Rissoan MC, et al. Thromboresistance of bulk heparinized catheters in human. Thrombosis Research 1987;45(3):223-33.
104. Epperson EL. Efficacy of 0.9% sodium chloride injection with and without heparin for maintaining indwelling intermittent injection sites. Clinical Pharmacy 1984;3(6):626-9.
105. Everts R, Harding H. Catheter-drawn blood cultures: is withdrawing the heparin lock beneficial?. Pathology 2004;36(2):170-3.
106. Ferreira Chacon JM, Hato De Almeida E, De Lourdes Simoes R, Lazzarin C, Ozorio V, Alves BC, Mello De Andrea ML, et al. Randomized study of minocycline and edetic acid as a locking solution for central line (Port-A-Cath) in children with cancer. Chemotherapy 2011;57(4):285-91.
107. Festini F. Normal saline Versus heparinized solution flush for maintaining patency of peripheral venous catheters in children. http://clinicaltrials.gov/ct2/show/NCT01794767?term=Normal+Saline+Versus+Heparinized+Solution+Flush+for+Maintaining+Patency+of+Peripheral+Venous+Catheters+in+Children&rank=1 (accessed 6 October 2014) 2013.
108. Filippi L, Pezzati M, Di Amario S, Poggi C, Pecile P. Fusidic acid and heparin lock solution for the prevention of catheter-related bloodstream infections in critically ill neonates: a retrospective study and a prospective, randomized trial. Pediatric Critical Care Medicine 2007;8(6):556-62.
109. Fonseca UNK, Nielsen SG, Hau J, Hansen AK. Permanent catheterization of the carotid artery induces kidney infection and inflammation in the rat. Laboratory Animals 2010;44(1):46-53.
110. Fort AE, Cummings JJ. Journal of Investigative Medicine Conference: American Federation for Medical Research Southern Regional Meeting, AFMR 2011. [A prospective, randomized, blinded, placebo-controlled trial of periodic, brief ethanol locks to prevent peripherally inserted central catheter (PICC) infections in preterm infants in the neonatal intensive care unit]. Journal of Investigative Medicine. 2011; Vol. 59, issue 2:175.
111. Fratino G, Molinari AC, Mazzola C, Giacchino M, Saracco P, Bertocchi E, et al. Prospective study of indwelling central venous catheter-related complications in children with broviac or clampless valved catheters. Journal of Pediatric Hematology/Oncology 2002;24(8):657-61.
112. Garay Rubio T, Urruela Oliván M, Hernando Uzkudun A, Asensio Bermejo B, Cossío Díaz C. Efectivity [sic] of saline versus heparinized solution in flushing clogged peripheral catheter [Efectividad en la utilización de suero salino frente a suero salino heparinizado para el lavado de catéteres periféricos obturados]. Enfermeria Clinica 2011;11(6):283-8.
113. Garland JS, Alex CP, Henrickson KJ, McAuliffe TL, Maki DG. A vancomycin-heparin lock solution for prevention of nosocomial bloodstream infection in critically ill neonates with peripherally inserted central venous catheters: a prospective, randomized trial. Pediatrics 2005;116(2):e198-205.
114. Garrelts JC, LaRocca J, Ast D, Smith DF Jr, Sweet DE. Comparison of heparin and 0.9% sodium chloride injection in the maintenance of indwelling intermittent i.v. devices. Clinical Pharmacy 1989;8(1):34-9.
115. Gillies H, Rogers HJ, Johnston J, Harper PG, Rudge CJ. Is repeated flushing of Hickman catheters necessary?. British Medical Journal (Clinical Research Edition) 1985;290(6483):1708.
116. Gittins NS, Hunter-Blair YL, Matthews JN, Coulthard MG. Comparison of alteplase and heparin in maintaining the patency of paediatric central venous haemodialysis lines: a randomised controlled trial. Archives of Disease in Childhood 2007;92(6):499-501.
117. Glaspy JA. A phase III randomized, double-blind, placebo-controlled study to evaluate the effects of fragmin (5, 000 IU subcutaneously) in preventing catheter-related complications when given daily to cancer patients with central venous catheters. http://clinicaltrials.gov/ct2/show/NCT00006083?term=Dalteparin+to+Prevent+Complications+in+Cancer+Patients+Receiving+Chemotherapy+Through+a+Catheter&rank=1 (accessed 6 October 2014) 2000.
118. Goh LJ, Teo HS, Masagoes M. Heparinised saline versus normal saline in maintaining patency of arterial and central venous catheters. Proceedings of Singapore Healthcare 2011;20(3):190-6.
119. Golberg M, Sankaran R, Givelichian L, Sankaran K. Maintaining patency of peripheral intermittent infusion devices with heparinized saline and saline: a randomized double blind controlled trial in neonatal intensive care and a review of literature. Neonatal Intensive Care 1999;12(1):18-22.
120. Gomez Palomar C, Gomez Palomar MJ. Comparison of the yield of arterial cannulas maintained with heparinized and nonheparinized fluids: a prospective study [Comparación en el rendimiento de cánulas arteriales mantenidas con fluidos heparinizados y no heparinizados: estudio prospectivo]. Enfermeria Clinica 2005;15(5):262-6.
121. Goode CJ, Kleiber C, Titler M, Small S, Rakel B, Steelman VM, et al. Improving practice through research: the case of heparin vs. saline for peripheral intermittent infusion devices. MEDSURG Nursing 1993;2(1):23-7.
122. Griffin MP, Siadaty MS. Papaverine prolongs patency of peripheral arterial catheters in neonates. Journal of Pediatrics 2005;146(1):62-5.
123. Grosso P, Martello L, Petrini PL, Massei R. Prevention of vena cava thrombosis during catheterization. Comparison of calciheparin and defibrotide. Minerva Anestesiologica 1989;55(6):273-6.
124. Guillet P, La Scola B, Bagarry-Liegey D, Lorvellec K, Martin N, Nicoara A, et al. Clinical pilot study on repeated use of heparin, vancomycin, colimycine locked flush solution for central intravenous implanted catheter in oncology [Etude clinique pilote de l'utilisation repétée dune solution héparine, vancomycine, colimycine en verrouillage systématique des chambres implantables avec cathéter centeral en cancérologie]. Pathologie-Biologie 1997;45(6):506-13.
125. Gyr P, Burroughs T, Smith K, Mahl C, Pontious S, Swerczek L. Double blind comparison of heparin and saline flush solutions in maintenance of peripheral infusion devices. Pediatric Nursing 1995;21(4):383-9. 366.
126. Hall KF, Bennetts TM, Whitta RK, Welman L, Rawlins P. Effect of heparin in arterial line flushing solutions on platelet count: a randomised double-blind study. Critical Care and Resuscitation 2006;8(4):294-6.
127. Hamilton RA, Plis JM, Clay C, Sylvan L. Heparin sodium versus 0.9% sodium chloride injection for maintaining patency of indwelling intermittent infusion devices. Clinical Pharmacy 1988;7(6):439-43.
128. Handrup MM, Fuursted K, Funch P, Møller JK, Schrøder H. Biofilm formation in long-term central venous catheters in children with cancer: a randomized controlled open-labelled trial of taurolidine versus heparin. Acta Pathologica Microbiologica Immunologica Scandinavica 2012;120(10):794-801.
129. Handrup MM, Moller JK, Schroder H. Central venous catheters and catheter locks in children with cancer: a prospective randomized trial of taurolidine versus heparin. Pediatric Blood & Cancer 2013;60(8):1292-8.
130. Hanrahan KS, Kleiber C, Fagan CL. Evaluation of saline for IV locks in children. Pediatric Nursing 1994;20(6):549-52.
131. Harlev D, Zaidman I, Sarig G, Ben Arush MW, Brenner B, Elhasid R. Prophylactic therapy with enoxaparin in children with acute lymphoblastic leukemia and inherited thrombophilia during L-asparaginase treatment. Thrombosis Research 2010;126(2):93-7.
132. Harter C, Salwender HJ, Bach A, Egerer G, Goldschmidt H, Ho AD. Catheter-related infection and thrombosis of the internal jugular vein in hematologic-oncologic patients undergoing chemotherapy: a prospective comparison of silver-coated and uncoated catheters. Cancer 2002;94(1):245-51.
133. Haynes BJ, Quarles AW, Vavrinchik J, White J, Pedan A. The LifeSite hemodialysis access system: implications for the nephrology nurse. Nephrology Nursing Journal 2002;29(1):27-33, 72.
134. Heilskov J, Kleiber C, Johnson K, Miller J. A randomized trial of heparin and saline for maintaining intravenous locks in neonates. Journal of the Society of Pediatric Nurses 1998;3(3):111-6.
135. Hemmelgarn BR, Moist L, Pilkey RM, Lok C, Dorval M, Tam PYW, et al.and the Canadian Hemodialysis Catheter Working Group. Prevention of catheter lumen occlusion with rT-PA versus heparin (Pre-CLOT): Study protocol of a randomized trial [ISRCTN35253449]. BMC Nephrology 2006;7:8.
136. Hemmelgarn BR, Moist LM, Lok CE, Tonelli M, Manns BJ, Holden RM, et al.for the Prevention of Dialysis Catheter Lumen Occlusion with rt-PA versus Heparin (PreCLOT) Study Group. Prevention of dialysis catheter malfunction with recombinant tissue plasminogen activator. New England Journal of Medicine 2011;364(4):303-12.
137. Hendrickx L, Kuypers D, Evenepoel P, Maes B, Messiaen T, Vanrenterghem Y. A comparative prospective study on the use of low concentrate citrate lock versus heparin lock in permanent dialysis catheters. International Journal of Artificial Organs 2001;24(4):208-11.
138. Heng A-E, Abdelkader MH, Diaconita M, Nony A, Guerraoui A, Caillot N, et al. Impact of short term use of interdialytic 60% ethanol lock solution on tunneled silicone catheter dysfunction. Clinical Nephrology 2011;75(6):534-41.
139. Henrickson KJ, Axtell RA, Hoover SM, Kuhn SM, Pritchett J, Kehl SC, et al. Prevention of central venous catheter-related infections and thrombotic events in immunocompromised children by the use of vancomycin/ciprofloxacin/heparin flush solution: A randomized, multicenter, double-blind trial. Journal of Clinical Oncology 2000;18(6):1269-78.
140. HGU Gregorio Marañón. Clinical study of ethanol lock-therapy in the prevention of non-tunnelled, short term central venous catheter associated infections. http://clinicaltrials.gov/ct2/show/NCT01229592 (accessed 6 October 2014) 2010.
141. Hill SM, Chu H-P, Koeglmeier J, Brind J, Turner S, Penfold-Forbes D, et al. Significant reduction in catheter-related bloodstream infections with taurolidine lock in children treated with intravenous nutrition for 16, 000 catheter days. Journal of Pediatric Gastroenterology and Nutrition 2011;52(Suppl 1):E64.
142. Hoffer EK, Borsa J, Santulli P, Bloch R, Fontaine AB. Prospective randomized comparison of valved versus nonvalved peripherally inserted central vein catheters. AJR. American Journal of Roentgenology 1999;173(5):1393-8.
143. Hook ML, Reuling J, Luettgen ML, Norris SO, Elsesser CC, Leonard MK. Comparison of the patency of arterial lines maintained with heparinized and nonheparinized infusions. The Cardiovascular Intensive Care Unit Nursing Research Committee of St. Luke's Hospital. Heart and Lung 1987;16(6 Pt 1):693-9.
144. Horgan MJ, Bartoletti A, Polansky S, Peters JC, Manning TJ, Lamont BM. Effect of heparin infusates in umbilical arterial catheters on frequency of thrombotic complications. Journal of Pediatrics 1987;111(5):774-8.
145. Horne MK III, May DJ, Alexander HR, Steinhaus EP, Whitman ED, Chang RC, et al. Venographic surveillance of tunneled venous access devices in adult oncology patients. Annals of Surgical Oncology 1995;2(2):174-8.
146. Horne MK, McCloskey DJ, Calis K, Wesley R, Childs R, Kasten-Sportes C. Use of heparin versus lepirudin flushes to prevent withdrawal occlusion of central venous access devices. Pharmacotherapy 2006;26(9):1262-7.
147. Hryszko T, Brzosko S, Mysliwiec M. Low concentration of heparin used for permanent catheters canal locking is effective and diminishes the risk of bleeding. International Urology and Nephrology 2013;45(3):825-9.
148. Hu HH, Hsu CY, Fang HC, Lee PT, Chen CL, Chang TY, et al. Low-dose heparin retention in temporary hemodialysis double-lumen catheter does not increase catheter occlusion and might reduce risk of bleeding. Blood Purification 2011;32(3):232-7.
149. Imamovic G. Randomized control trial on citrate as the central venous catheter lock solution. http://clinicaltrials.gov/ct2/show/NCT00862966?term=Central+Venous+Catheter+Lock+Solution&rank=1 (accessed 6 October 2014) 2009.
150. Ishii Y, Mishima S, Yukioka T. Comparison of normal saline and heparinized solutions for maintenance of arterial catheter pressure waves. Academic Emergency Medicine 2013;20(5 Suppl 1):s248.
151. Israel Ministry of Health. Addition of heparin to taurolock-TM CLS in HD patients with TCC does it improve catheter patency problems ?. http://clinicaltrials.gov/ct2/show/NCT00749619?term=Addition+of+Heparin+to+Taurolock-TM+CLS+in+HD+Patients+With+TCC+Dose+it+Improve+Catheter+Patency+Problems+%3F&rank=1 (accessed 6 October 2014) 2008.
152. Jaksic T. Trial of 70% ethanol versus heparin to reduce the rate of central line infections in children with short bowel syndrome. http://clinicaltrials.gov/ct2/show/NCT01263574?term=Trial+of+70%25+Ethanol+Versus+Heparin+to+Reduce+the+Rate+of+Central+Line+Infections+in+Children+With+Short+Bowel+Syndrome&rank=1 (accessed 6 October 2014) 2010.
153. James C. Commentary on changing from heparin to saline flush solutions: a research utilization model for implementation. ENA'S Nursing Scan in Emergency Care 1994;4(1):22.
154. Jasinsky L, Wurster J. Occlusion reduction and heparin elimination trial using an anti-reflux device on central intravenous lines. Journal of the Association for Vascular Access 2007;12(4):205.
155. Jeppesen PB. A double blinded, randomized, controlled investigation of taurolidine-citrate/eparin catheter lock solution versus heparin in patients on home parenteral nutrition with previously proven high risk of catheter related blood stream infections. http://clinicaltrials.gov/ct2/show/NCT01948245?term=Clinical+Trial+Comparing+Catheter+Lock+Solutions+TaurolockTMHep+100+and+Heparin+100+IE%2Fml&rank=1 (accessed 6 October 2014) 2013.
156. Johnson DW, MacGinley R, Kay TD, Hawley CM, Campbell SB, Isbel NM, et al. A randomized controlled trial of topical exit site mupirocin application in patients with tunnelled, cuffed haemodialysis catheters. Nephrology Dialysis Transplantation 2002;17(10):1802-7.
157. Jonker MA, Osterby KR, Vermeulen LC, Kleppin SM, Kudsk KA. Does low-dose heparin maintain central venous access device patency?: a comparison of heparin versus saline during a period of heparin shortage. JPEN Journal of Parenteral and Enteral Nutrition 2010;34(4):444-9.
158. Jonkers C, Looman KI, Tabbers MM, Tas TA, Serlie MJ. Incidence of central venous catheter related bloodstream infections in adults and children on home parenteral nutrition: Heparin versus taurolidine catheter lock. Clinical Nutrition Supplements 2012;7(1):203-4.
159. Jowett NI, Stephens JM, Thompson DR, Sutton TW. Do indwelling cannulae on coronary care units need a heparin flush?. Intensive Care Nursing 1986;2(1):16-9.
160. Kalmanti M, Germanakis J, Stiakaki E, Syfridaki C, Christidou A, Tsetis D, et al. Prophylaxis with urokinase in pediatric oncology patients with central venous catheters. Pediatric Hematology and Oncology 2002;19(3):173-9.
161. Kamala F, Boo NY, Cheah FC, Birinder K. Randomized controlled trial of heparin for prevention of blockage of peripherally inserted central catheters in neonates. Acta Paediatrica 2002;91(12):1350-6.
162. Kankanala S, Smith K, Henner DE. Efficacy and safety of a 4% sodium citrate locking solution in cuffed tunneled hemodialysis catheters compared with heparin. American Journal of Kidney Diseases 2012;59(4):A45.
163. Karthaus M, Kretzschmar A, Kroning H, Biakhov M, Irwin D, Marschner N, et al. Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. Annals of Oncology 2006;17(2):289-96.
164. Kleiber C, Hanrahan K, Fagan CL, Zittergruen MA. Heparin vs. saline for peripheral IV locks in children. Pediatric Nursing 1993;19(4):405-9, 376.
165. Klenner AF, Fusch C, Rakow A, Kadow I, BeyersdorffE, Eichler P, et al. Benefit and risk of heparin for maintaining peripheral venous catheters in neonates: a placebo-controlled trial. Journal of Pediatrics 2003;143(6):741-5.
166. Knofler R, Siegert E, Lauterbach I, Taut-Sack H, Siegert G, Gehrisch S, et al. Clinical importance of prothrombotic risk factors in pediatric patients with malignancy - impact of central venous lines. European Journal of Pediatrics 1999;158(Suppl 3):S147-S150.
167. Kokenge T, Lohofener C, Lange C, Grundemann C, Bergmann K, Januschkewitz K, et al. Efficacy and safety of a low-dose citrate catheter locking solution. A randomized double blind controlled trial. NDT Plus 2010;3(3):iii162.
168. Kotter RW. Heparin vs saline for intermittent intravenous device maintenance in neonates. Neonatal Network 1996;15(6):43-7.
169. Kovacs MJ. A pilot study of central venous catheter survival in cancer patients using low molecular weight heparin (dalteparin) for the treatment of deep vein thrombosis of the upper extremity. http://clinicaltrials.gov/ct2/show/NCT00216866?term=The+Catheter+Study%3A+Central+Venous+Catheter+Survival+in+Cancer+Patients+Using+Low+Molecular+Weight+Heparin+%28Dalteparin%29+for+the+Treatment+of+Deep+Vein+Thrombosis&rank=1 (accessed 6 October 2014) 2005.
170. Krafte-Jacobs B, Sivit CJ, Mejia R, Pollack MM. Catheter-related thrombosis in critically ill children: comparison of catheters with and without heparin bonding. Journal of Pediatrics 1995;126(1):50-4.
171. Kristinsson KG, Hastings JGM, Spencer RC. Is repeated flushing of Hickman catheters necessary?. British Medical Journal 1985;291(6490):282.
172. Kudsk KA, Powell C, Mirtallo JM, Fabri PJ, Ruberg RL. Heparin does not reduce catheter sepsis during total parenteral nutrition. Journal of Parenteral and Enteral Nutrition 1985;9(3):348-9.
173. Kulkarni M, Elsner C, Ouellet D, Zeldin R. Heparinized saline versus normal saline in maintaining patency of the radial artery catheter. Canadian Journal of Surgery 1994;37(1):37-42.
174. Kyle LA, Turner BS. Efficacy of saline vs heparin in maintaining 24-gauge intermittent intravenous catheters in a rabbit model. Neonatal Network 1999;18(6):49-54.
175. Lacasaña Bellmunt P, Garcia Ortega MJ, Garcia Ruiz C, Palomino Gutierrez B, Toro Padilla R, Vila Sanchez A, Cánovas Galera P, Canals Tur R. Permeabilisation of peripheral venous catheters of intermittent use: with and without heparin [Permeabilización de catéteres venosos periféricos de uso intermitente: con y sin heparina]. Metas de Enfermeria 2006;9(7):10-6.
176. Lavau-Denes S, Lacroix P, Maubon A, Preux PM, Genet D, Venat-Bouvet L, et al. Prophylaxis of catheter-related deep vein thrombosis in cancer patients with low-dose warfarin, low molecular weight heparin, or control: a randomized, controlled, phase III study. Cancer Chemotherapy and Pharmacology 2013;72(1):65-73.
177. Le Corre I, Delorme M, Cournoyer S. A prospective, randomized trial comparing a transparent dressing and a dry gauze on the exit site of long term central venous catheters of hemodialysis patients. Journal of Vascular Access 2003;4(2):56-61.
178. LeDuc K. Efficacy of normal saline solution versus heparin solution for maintaining patency of peripheral intravenous catheters in children. Journal of Emergency Nursing 1997;23(4):306-9.
179. Lee AY, Levine MN, Butler G, Webb C, Costantini L, Gu C, et al. Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. Journal of Clinical Oncology 2006;24(9):1404-8.
180. Lenhart C. Preventing central venous access device occlusions with saline only flush by use of an adapter. Journal of Vascular Access Devices 2001;6(2):29-31.
181. Leslie GD, Jacobs IG, Clarke GM. Proximally delivered dilute heparin does not improve circuit life in continuous venovenous haemodiafiltration. Intensive Care Medicine 2011;22(11):1261-4.
182. Liang Y, Wang Y, Li D. Clinical observation on normal saline of tube-sealing solution for vein permanent needle. Shanxi Nursing Journal 1998;12(2):80-1.
183. Liao S, Zhang Y, Chen L. Comparison of effects on sealing up the infusion tube by using three different solutions. Chinese Nursing Research 2002;16(2):87-8.
184. Lindblad B, Bergqvist D, Wakefield TW, Stanley JC. Time-related anticoagulation after regional and systemic administration of heparin in patients undergoing aortoiliac surgery. European Journal of Vascular Surgery 1994;8(5):574-7.
185. Lok CE, Appleton D, Bhola C, Khoo B, Richardson RMA. Trisodium citrate 4% - an alternative to heparin capping of haemodialysis catheters. Nephrology Dialysis Transplantation 2007;22(2):477-83.
186. Lombardi TP, Gundersen B, Zammett LO, Walters JK, Morris BA. Efficacy of 0.9% sodium chloride injection with or without heparin sodium for maintaining patency of intravenous catheters in children. Clinical Pharmacy 1988;7(11):832-6.
187. Long DA, Coulthard MG. Effect of heparin-bonded central venous catheters on the incidence of catheter-related thrombosis and infection in children and adults. Anaesthesia and Intensive Care 2006;34(4):481-4.
188. Lustig A, Aflalu S. Novel catheter lock solution in prevention of hemodialysis catheter complications. Journal of Clinical Pharmacology 2011;51(9):1342.
189. Macrae JM, Dojcinovic I, Djurdjev O, Jung B, Shalansky S, Levin A, Kiaii M. Citrate 4% versus heparin and the reduction of thrombosis study (CHARTS). Clinical Journal of the American Society of Nephrology 2008;3(2):369-74.
190. Maki DG, Ash SR, Winger RK, Lavin P, AZEPTIC Trial Investigators. A novel antimicrobial and antithrombotic lock solution for hemodialysis catheters: a multi-center, controlled, randomized trial. Critical Care Medicine 2011;39(4):613-20.
191. Male C, Julian JA, Massicotte P, Gent M, Mitchell L, PROTEKT Study Group. Significant association with location of central venous line placement and risk of venous thrombosis in children. Thrombosis and Haemostasis 2005;94(3):516-21.
192. Malo J, Jolicoeur C, Theriault F, Lachaine J, Senecal L. Comparison between standard heparin and tinzaparin for haemodialysis catheter lock. ASAIO Journal (American Society for Artificial Internal Organs) 2010;56(1):42-7.
193. Marin MG, Lee JC, Skurnick JH. Prevention of nosocomial bloodstream infections: effectiveness of antimicrobial-impregnated and heparin-bonded central venous catheters. Critical Care Medicine 2000;28(9):3332-8.
194. Martin JM. Ethanol lock therapy for the prevention of catheter related blood stream infections. http://clinicaltrials.gov/ct2/show/NCT00948441?term=Pediatric+Ethanol+Lock+Therapy+Study&rank=1 (accessed 6 October 2014) 2009.
195. Masroujeh R, Shamseddeen W, Isma'eel H, Otrock ZK, Khalil IM, Taher A. Underutilization of venous thromboembolism prophylaxis in medical patients in a tertiary care center. Journal of Thrombosis and Thrombolysis 2008;26(2):138-41.
196. Massicotte P, Adams M, Marzinotto V, Brooker LA, Andrew M. Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study. Journal of Pediatrics 1996;128(3):313-8.
197. Massicotte P, Julian JA, Gent M, Shields K, Marzinotto V, Szechtman B, et al. PROTEKT Study Group. An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial. Thrombosis Research 2003;109(2-3):101-8.
198. Mayo DJ, Dimond EP, Kramer W, Horne MK III. Discard volumes necessary for clinically useful coagulation studies from heparinized Hickman catheters. Oncology Nursing Forum 1996;23(4):671-5.
199. McIntyre CW, Hulme LJ, Taal M, Fluck RJ. Locking of tunneled hemodialysis catheters with gentamicin and heparin. Kidney International 2004;66(2):801-5.
200. McMullen A, Fioravanti ID, Pollack V, Rideout K, Sciera M. Heparinized saline or normal saline as a flush solution in intermittent intravenous lines in infants and children. MCN: The American Journal of Maternal Child Nursing 1993;18(2):78-85.
201. Meier P, Meier R, Turini P, Friolet R, Blanc E. Prolonged catheter survival in patients with acute kidney injury on continuous renal replacement therapy using a less thrombogenic micropatterned polymer modification. Nephrology Dialysis Transplantation 2011;26(2):628-35.
202. Mendarte L, Aguas M, Pons M, Torres MD. Use of sodium heparin vs physiological serum in permeability of peripheral vias. Farmacia Hospitalaria 1997;21(4):222-6.
203. Meyer BA, Little CJ, Thorp JA, Cohen GR, Yeast JD. Heparin versus normal saline as a peripheral line flush in maintenance of intermittent intravenous lines in obstetric patients. Obstetrics and Gynecology 1995;85(3):433-6.
204. Meyer AD, Jacobs BR. Prevention of catheter-related thrombosis after cardiac surgery: is heparin the answer?. Pediatric Critical Care Medicine 2010;11(4):531-2.
205. Mismetti P, Mille D, Laporte S, Charlet V, Buchmuller-Cordier A, Jacquin JP, et al. CIP Study Group. Low-molecular-weight heparin (nadroparin) and very low doses of warfarin in the prevention of upper extremity thrombosis in cancer patients with indwelling long-term central venous catheters: a pilot randomized trial. Haematologica 2003;88(1):67-73.
206. Mitchell L, Andrew M, Hanna K, Abshire T, Halton J, Wu J, et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia: Results of the PARKAA study. Thrombosis and Haemostasis 2003;90(2):235-44.
207. Mok E, Kwong TK, Chan MF. A randomized controlled trial for maintaining peripheral intravenous lock in children. International Journal of Nursing Practice 2007;13(1):33-45.
208. Monreal M, Alastrue A, Rull M, Mira X, Muxart J, Rosell R, et al. Upper extremity deep venous thrombosis in cancer patients with venous access devices--prophylaxis with a low molecular weight heparin (Fragmin). Thrombosis and Haemostasis 1996;75(2):251-3.
209. Moran J, Sun S, Khababa I, Pedan A, Doss S, Schiller B. A randomized trial comparing gentamicin/citrate and heparin locks for central venous catheters in maintenance hemodialysis patients. American Journal of Kidney Diseases 2012;59(1):102-7.
210. Mortazavi M, Alsaeidi S, Sobhani R, Salimi F, Atapour A, Sharif N, et al. Succesful prevention of tunneled, central catheter infection by antibiotic lock therapy using cefotaxime. Journal of Research in Medical Sciences 2011;16(3):303-9.
211. Mudge B, Forcier D, Slattery MJ. Patency of 24-gauge peripheral intermittent infusion devices: a comparison of heparin and saline flush solutions. Pediatric Nursing 1998;24(2):142-5, 149.
212. Myrianthefs P, Sifaki M, Samara I, Baltopoulos G. The epidemiology of peripheral vein complications: evaluation of the efficiency of differing methods for the maintenance of catheter patency and thrombophlebitis prevention. Journal of Evaluation in Clinical Practice 2005;11(1):85-9.
213. Na HS. Influence by heparinized flush solution of the radial artery catheter: INTEM and HEPTEM analysis. http://clinicaltrials.gov/ct2/show/NCT01522846?term=Heparin+Solution+and+INTEM%2FHEPTEM+Analysis&rank=1 (accessed 6 October 2014) 2012.
214. Niers TMH, Di Nisio M, Klerk CPW, Baarslag HJ, Buller HR, Biemond BJ. Prevention of catheter-related venous thrombosis with nadroparin in patients receiving chemotherapy for hematologic malignancies: a randomized, placebo-controlled study. Journal of Thrombosis and Haemostasis 2007;5(9):1878-82.
215. Niesen KM, Harris DY, Parkin LS, Henn LT. The effects of heparin versus normal saline for maintenance of peripheral intravenous locks in pregnant women. Journal of Obstetric Gynecologic and Neonatal Nursing 2003;32(4):503-8.
216. Nieto-Rodriguez JA, Garcia-Martin MA, Barreda-Hernandez MD, Hervas MJ, Cano-Real O. Heparin and infusion phlebitis: a prospective study. Annals of Pharmacotherapy 1992;26(10):1211-4.
217. NIH Clinical Centers. Heparin vs. lepirudin flushes in preventing withdrawal occlusion of tunneled, open-ended venous access devices: a blinded, randomized, clinical trial. http://clinicaltrials.gov/ct2/show/NCT00039767?term=Heparin+Versus+Lepirudin+Flushes+in+Preventing+Blockage+of+Venous+Access+Devices&rank=1 (accessed 6 October 2014) 2002.
218. Nori US, Manoharan A, Yee J, Besarab A. Comparison of low-dose gentamicin with minocycline as catheter lock solutions in the prevention of catheter-related bacteremia. American Journal of Kidney Diseases 2006;48(4):596-605.
219. Ociepa T, Maloney E, Urasinski T, Sawicki M. Thrombotic complications of tunneled central lines in children with malignancy. Journal of Pediatric Hematology/Oncology 2010;32(2):88-92.
220. Oguzhan N, Pala C, Sipahioglu MH, Cilan H, Durmaz S, Percin D, et al. Locking tunneled hemodialysis catheters with hypertonic saline (26% NaCl) and heparin to prevent catheter-related bloodstream infections and thrombosis: a randomised, prospective trial. Renal Failure 2012;34(2):181-8.
221. Ojala TH, Lehtonen L. A preliminary report - heparin counteracts indomethacin effect on ductus arteriosus in very low birthweight infants. Pediatric Critical Care Medicine 2007;8(3):258-60.
222. Onder AM, Chandar J, Billings A, Simon N, Gonzalez J, Francoeur D, et al. Prophylaxis of catheter-related bacteremia using tissue plasminogen activator-tobramycin locks. Pediatric Nephrology 2009;24(11):2233-43.
223. Oran NT, Eser I. Impact of heparin locking frequency on preventing temporary dialysis catheter dysfunction in haemodialysis patients. Journal of Renal Care 2008;34(4):199-202.
224. Paisley MK, Stamper M, Brown J, Brown N, Ganong LH. The use of heparin and normal saline flushes in neonatal intravenous catheters. Pediatric Nursing 1997;23(5):521-4, 527.
225. Periard D, Monney P, Waeber G, Zurkinden C, Mazzolai L, Hayoz D, et al. Randomized controlled trial of peripherally inserted central catheters vs. peripheral catheters for middle duration in-hospital intravenous therapy. Journal of Thrombosis and Haemostasis 2008;6(8):1281-8.
226. Pervez A, Ahmed M, Ram S, Torres C, Work J, Zaman F, et al. Antibiotic lock technique for prevention of cuffed tunnel catheter associated bacteremia. Journal of Vascular Access 2002;3(3):108-13.
227. Petersen C. Clinical issues. Heparin v saline locks; "hosing"reading in the OR; sterility of dropped packages; trays as prep table covers. AORN Journal 2001;74(6):900-3.
228. Pierce CM, Wade A, Mok Q. Heparin-bonded central venous lines reduce thrombotic and infective complications in critically ill children. Intensive Care Medicine 2000;26(7):967-72.
229. Pouw L, Kilsby D, Francis P, Tulloh B. Heparin thromboprophylaxis via indwelling subcutaneous teflon cannula. Australian and New Zeland Journal of Surgery 1995;65(11):793-5.
230. Power A, Duncan N, Singh SK, Brown W, Dalby E, Edwards C, et al. Sodium citrate versus heparin catheter locks for cuffed central venous catheters: a single-center randomized controlled trial. American Journal of Kidney Diseases 2009;53(6):1034-41.
231. Powers JM. Obtaining blood samples for coagulation studies from a normal saline lock. American Journal of Critical Care 1999;8(4):250-3.
232. Pucheu A, Leduc B, Sillet-Bach I, Payen C, Assaf W, Pucheu M. Experimental prevention of deep venous thrombosis with low-molecular-weight heparin using implantable infusion devices [Prevention experimental de la thrombose veineuse profonde avec de l'heparine de bas poids moleculaire en usant dispositifs d'infusion implantables]. Annales de Cardiologie et d Angeiologie 1996;45(2):59-63.
233. Puiggròs C, Cuerda C, Virgili N, Chicharro ML, Martínez C, Garde C, Grupo NADYA-SENPE. Catheter occlusion and venous thrombosis prevention and incidence in adult home parenteral nutrition (HPN) programme patients [Prevención e incidencia de oclusión del catéter y trombosis venosa en pacientes adultos con nutrición parenteral domiciliaria (NPD)]. Nutricion Hospitalaria 2012;27(1):256-61.
234. Quenot JP. Citrate versus heparin for the lock of non-tunneled hemodialysis catheters in patients hospitalised in ICU. Multicentre, controlled, randomised superiority trial. http://clinicaltrials.gov/ct2/show/NCT01962116?term=Citrate+Versus+Heparin+for+the+Lock+of+Non-tunneled+Hemodialysis+Catheters+in+Patients+Hospitalised+in+ICU&rank=1 (accessed 6 October 2014) 2013.
235. RackoffWR, Weiman M, Jakobowski D, Hirschl R, Stallings V, Bilodeau J, et al. A randomized, controlled trial of the efficacy of a heparin and vancomycin solution in preventing central venous catheter infections in children. Journal of Pediatrics 1995;127(1):147-51.
236. Rajani K, Goetzman BW, Wennberg RP, Turner E, Abildgaard C. Effect of heparinization of fluids infused through an umbilical artery catheter on catheter patency and frequency of complications. Pediatrics 1979;63(4):552-6.
237. Randon C. Prospective study which compares the use of a closing system without a needle and with positive pressure to a heparin lock with positive pressure for patients with a catheter for chemotherapy. http://clinicaltrials.gov/ct2/show/NCT00386451?term=Comparing+a+Closing+System+Without+a+Needle+With+Positive+Pressure+to+a+Heparin+Lock+With+Positive+Pressure&rank=1 (accessed 6 October 2014) 2006.
238. Rao PS, Thapar MK, Rogers JH, Jr, Strong WB, Lutcher CL, Nesbit RR, Jr, et al. Effect of intraarterial injection of heparin on the complications of percutaneous arterial catheterization in infants and children. Catheterization and Cardiovascular Diagnosis 1981;7(3):235-46.
239. Ray CE Jr, Shenoy SS, McCarthy PL, Broderick KA, Kaufman JA. Weekly prophylactic urokinase instillation in tunneled central venous access devices. Journal of Vascular and Interventional Radiology 1999;10(10):1330-4.
240. Reeves AM. Comparison of heparin vs. no heparin on duration of peripherally inserted central catheter patency in neonates. http://clinicaltrials.gov/ct2/show/NCT00879957?term=Heparin+Versus+no+Heparin+on+Duration+of+Peripherally+Inserted+Central+Catheter+%28PICC%29+Patency+in+Neonates&rank=1 (accessed 6 October 2014) 2009.
241. Reichardt P, Kretzschmar A, Biakhov M, Irwin D, Slabber C, Miller L, et al. A phase III double-blind, placebo-controlled study evaluating the efficacy and safety of daily low-molecular-weight heparin (dalteparin sodium, Fragmin) in preventing catheter-related complications in cancer patients with central venous catheters [abstract]. Journal of Clinical Oncology 2002; Vol. 21 (Suppl):703a, Abstract 1474.
242. Renaud CJ, Serret D, Sinon E. Antimicrobial locks in tunneled hemodialysis catheters: from clinical trials to clinical practice. Hemodialysis International 2009;13(3):375.
243. Rijnders BJ, Van WE, Vandecasteele SJ, Stas M, Peetermans WE. Treatment of long-term intravascular catheter-related bacteraemia with antibiotic lock: randomized, placebo-controlled trial. Journal of Antimicrobial Chemotherapy 2005;55(1):90-4.
244. Roberts GW, Holmes MD, Staugas RE, Day RA, Finlay CF, Pitcher A. Peripheral intravenous line survival and phlebitis prevention in patients receiving intravenous antibiotics: heparin/hydrocortisone versus in-line filters. Annals of Pharmacotherapy 1994;28(1):11-6.
245. Robertson J. Intermittent intravenous therapy: a comparison of two flushing solutions. Contemporary Nurse 1994;3(4):174-9.
246. Robinson M, Healey JS, Eikelboom J, Schulman S, Morillo CA, Nair GM, et al. Postoperative low-molecular-weight heparin bridging is associated with an increase in wound hematoma following surgery for pacemakers and implantable defibrillators. Pacing and Clinical Electrophysiology 2009;32(3):378-82.
247. Ruggiero RP, Aisenstein TJ. Central catheter fibrin sleeve - heparin effect. JPEN Journal of Parenteral and Enteral Nutrition 1983;7(3):270-3.
248. Sahin Balcik O, Akkaya C, Uz B, Aksoy C, Guvenc B, Dincer S. The efficacy and safety of hypertonic citrate as catheter-locking solution in hematopoietic stem cell transplant recipients [Hipertonik Sitratin Hematopoetik Kök Hücre Transplant Alicilarinda Kateter Kapatma Solüsyonu Olarak Etkinlik ve Güvenirligi]. Turkiye Klinikleri Journal of Cardiovascular Sciences 2011;23(1):48-53.
249. Sanders J, Pithie A, Ganly P, Surgenor L, Wilson R, Merriman E, Loudon G, Judkins R, Chambers S. A prospective double-blind randomized trial comparing intraluminal ethanol with heparinized saline for the prevention of catheter-associated bloodstream infection in immunosuppressed haematology patients. Journal of Antimicrobial Chemotherapy 2008;62(4):809-15.
250. Sang Sook H, Jee Eun P, Nam Eun K, Hwa Ja K. Effects of normal saline for maintenance of arterial lines of surgical patients. Journal of Korean Academy of Nursing 2012;42(6):791-8.
251. Saxena AK, Panhotra BR. The impact of catheter-restricted filling with cefotaxime and heparin on the lifespan of temporary hemodialysis catheters: a case controlled study. Journal of Nephrology 2005;18(6):755-63.
252. Saxena AK, Panhotra BR, Sundaram DS, Al-Hafiz A, Naguib M, Venkateshappa CK, et al. Tunneled catheters' outcome optimization among diabetics on dialysis through antibiotic-lock placement. Kidney International 2006;70(9):1629-35.
253. Saxena AK, Panhotra BR, Sundaram DS, Morsy MN, Al-Ghamdi AM. Enhancing the survival of tunneled haemodialysis catheters using an antibiotic lock in the elderly: a randomised, double-blind clinical trial. Nephrology 2006;11(4):299-305.
254. Scherr K, Guenther C, Koshal A, Finegan B. Effects of heparinized vs nonheparinized flush solutions on patency of arterial and central pressure monitoring lines in the postoperative cardiac surgical patient. American Journal of Critical Care 2002;11(3):277.
255. Schilling S, Doellman D, Hutchinson N, Jacobs BR. The impact of needleless connector device design on central venous catheter occlusion in children: a prospective, controlled trial. JPEN Journal of Parenteral and Enteral Nutrition 2006;30(2):85-90.
256. Schouten H. Concentrated citrate locking to reduce the incidence of central venous catheter-related infections and thrombosis: a randomized phase III study in a hematological patient population. http://clinicaltrials.gov/ct2/show/NCT01820962?term=Concentrated+Citrate+Locking+to+Reduce+the+Incidence+of+CVC-related+Complications+in+Hematological+Patients&rank=1 (accessed 6 October 2014) 2013.
257. Schroder H. A randomised study of taurolock for the locking of tunneled central venous catheters in children with malignant diseases. http://clinicaltrials.gov/ct2/show/NCT00735813?term=Taurolidine+Lock+Solution+in+the+Prevention+of+Catheter+Related+Bacteremia&rank=1 (accessed 6 October 2014) 2008.
258. Schroeder AR, Axelrod DM, Silverman NH, Rubesova E, Merkel E, Roth SJ. A continuous heparin infusion does not prevent catheter-related thrombosis in infants after cardiac surgery. Pediatric Critical Care Medicine 2010;11(4):489-95.
259. Schultz AA, Drew D, Hewitt H. Comparison of normal saline and heparinized saline for patency of IV locks in neonates. Applied Nursing Research 2002;15(1):28-34.
260. Schwartz C, Henrickson KJ, Roghmann K, Powell K. Prevention of bacteremia attributed to luminal colonization of tunneled central venous catheters with vancomycin-susceptible organisms. Journal of Clinical Oncology 1990;8(9):1591-7.
261. Seguin J, Fletcher MA, Landers S, Brown D, Macpherson T. Umbilical venous catheterizations: audit by the Study Group for Complications of Perinatal Care. American Journal of Perinatology 1994;11(1):67-70.
262. Seliem W, Abdel-Hady H, El-Nady G. Amikacin-heparin lock for prevention of catheter-related bloodstream infection in neonates with extended umbilical venous catheters use: a randomized controlled trial. Journal of Neonatal-Perinatal Medicine 2010;3(1):33-41.
263. Serrano Ruiz A, Saboya Sánchez S, Latorre Marco I, Bragado León M, Cabrerizo Osorio E, Solis Muñoz M, et al. Efficacy of a sealing solution with saline solution at 0, 9% versus heparin to maintain permeability of a central venous catheter at the ICU [Eficacia de una solución de sellado con suero salino al 0, 9% versus heparina sobre la permeabilidad del catéter venoso central no permanente en pacientes críticos]. Educare21 2009;53(7):http://www.enfermeria21.com/publicaciones/educare (accessed May 2012).
264. Shah PS, Kalyn A, Satodia P, Dunn MS, Parvez B, Daneman A, et al. A randomized, controlled trial of heparin versus placebo infusion to prolong the usability of peripherally placed percutaneous central venous catheters (PCVCs) in neonates: the HIP (Heparin Infusion for PCVC) study. Pediatrics 2007;119(1):e284-91.
265. Shen J, Montez-Rath M, Mitani A, Winkelmayer W. Correlates of and variation in heparin dosage for maintenance hemodialysis in older U.S. patients. American Journal of Kidney Diseases 2013;61(4):A89.
266. Shirzad M, Espahbodi F, Baboli MT, Samakoosh MA, Khalilian A. Effects of heparin lock-antibiotics to prevent infections in patients undergoing hemodialysis: a clinical trial. Journal of Mazandaran University of Medical Sciences 2013;22(96):99-104.
267. Shively M, Riegel B, Waterhouse D, Burns D, Templin K, Thomason T. Testing a community level research utilization intervention. Applied Nursing Research: ANR 1997;10(3):121-7.
268. Shoaf J, Oliver S. Efficacy of normal saline injection with and without heparin for maintaining intermittent intravenous site. Applied Nursing Research 1992;5(1):9-12.
269. Sierra Diaz R. Sealing catheters with gelafundin compared to sodium heparin [Sellado de catéteres con gelafundina versus heparina sódica]. Revista de la Sociedad Española de Enfermeria Nefrologica 2010;13(4):242-5.
270. Silva J, Teixeira e Costa, Baptista A, Ramos A, Ponce P. Catheter-related bacteremia in hemodialysis: which preventive measures to take?. Nephron 2008;110(4):251-7.
271. Silva TNV, Mendes ML, Abrao JMG, Caramori JT, Ponce D. Successful prevention of tunneled central catheter infection by antibiotic lock therapy using cefazolin and gentamicin. International Urology and Nephrology 2013;45(5):1405-13.
272. Skofic N, Buturovic-Ponikvar J, Kovac J, Premru V, Knap B, Pernat AM, et al. Hemodialysis catheters with citrate locking in critically ill patients with acute kidney injury treated with intermittent online hemofiltration or hemodialysis. Therapeutic Apheresis and Dialysis 2009;13(4):327-33.
273. Smith I, Hathaway M, Goldman C, Ng J, Brunton J, Simor AE, et al. A randomized study to determine complications associated with duration of insertion of heparin locks. Research in Nursing and Health 1990;13(6):367-73.
274. Smith S, Dawson S, Hennessey R, Andrew M. Maintenance of the patency of indwelling central venous catheters: is heparin necessary?. American Journal of Pediatric Hematology/Oncology 1991;13(2):141-3.
275. Sofroniadou S, Revela I, Smirloglou D, Makriniotou I, Zerbala S, Kouloubinis A, et al. Linezolid versus vancomycin antibiotic lock solution for the prevention of nontunneled catheter-related blood stream infections in hemodialysis patients: a prospective randomized study. Seminars in Dialysis 2012;25(3):344-50.
276. Solomon B, Moore J, Arthur C, Prince HM. Lack of efficacy of twice-weekly urokinase in the prevention of complications associated with Hickman catheters: a multicentre randomised comparison of urokinase versus heparin. European Journal of Cancer 2001;37(18):2379-84.
277. Solomon LR, Cheesbrough JS, Ebah L, Al-Sayed T, Heap M, Millband N, et al. A randomized double-blind controlled trial of taurolidine-citrate catheter locks for the prevention of bacteremia in patients treated with hemodialysis. American Journal of Kidney Diseases 2010;55(6):1060-8.
278. Solomon LR, Cheesbrough JS, Bhargava R, Mitsides N, Heap M, Green G, et al. Observational study of need for thrombolytic therapy and incidence of bacteremia using taurolidine-citrate-heparin, taurolidine-citrate and heparin catheter locks in patients treated with hemodialysis. Seminars in Dialysis 2012;25(2):233-8.
279. Sona C, Prentice D, Schallom L. National survey of central venous catheter flushing in the intensive care unit. Critical Care Nurse 2012;32(1):e12-9.
280. Stas KJF, Vanwalleghem J, De MB, Keuleers H. Trisodium citrate 30% vs heparin 5% as catheter lock in the interdialytic period in twin- or double-lumen dialysis catheters for intermittent haemodialysis. Nephrology Dialysis Transplantation 2001;16(7):1521-2.
281. Steczko J, Ash SR, Nivens DE, Brewer L, Winger RK. Microbial inactivation properties of a new antimicrobial/antithrombotic catheter lock solution (citrate/methylene blue/parabens). Nephrology Dialysis Transplantation 2009;24(6):1937-45.
282. Stephens LC, Haire WD, Tarantolo S, Reed E, Schmit-Pokorny K, Kessinger A, et al. Normal saline versus heparin flush for maintaining central venous catheter patency during apheresis collection of peripheral blood stem cells (PBSC). Transfusional Science 1997;18(2):187-93.
283. Taylor J, Shannon R, Kilbride HW. Heparin lock intravenous line. Use in newborn infants. Clinical Pediatrics 1989;28(5):237-40.
284. Thomson PC, Morris ST, Mactier RA. The effect of heparinized catheter lock solutions on systemic anticoagulation in hemodialysis patients. Clinical Nephrology 2011;75(3):212-7.
285. Thurlimann B, Bachmann I. Effective prevention of chemotherapy-induced phlebitis by low-dose heparin: a prospective randomised trial. Annals of Oncology 1992;3(4):311-3.
286. Tolar B, Gould JR. The timing and sequence of multiple device-related complications in patients with long-term indwelling Groshong catheters. Cancer 1996;78(6):1308-13.
287. Treas LS, Latinis-Bridges B. Efficacy of heparin in peripheral venous infusion in neonates. Journal of Obstetric, Gynecologic, and Neonatal Nursing 1992;21(3):214-9.
288. Trivedi HS, Twardowski ZJ. Use of double-lumen dialysis catheters. Loading with locked heparin. ASAIO Journal (American Society for Artificial Internal Organs) 1997;43(6):900-3.
289. Trottier SJ, Veremakis C, O'Brien J, Auer AI. Femoral deep vein thrombosis associated with central venous catheterization: results from a prospective, randomized trial. Critical Care Medicine 1995;23(1):52-9.
290. Tuncali BE, Kuvaki B, Tuncali B, Capar E. A comparison of the efficacy of heparinized and nonheparinized solutions for maintenance of perioperative radial arterial catheter patency and subsequent occlusion. Anesthesia and Analgesia 2005;100(4):1117-21.
291. Tuten SH, Gueldner SH. Efficacy of sodium chloride versus dilute heparin for maintenance of peripheral intermittent intravenous devices. Applied Nursing Research 1991;4(2):63-71.
292. Unal S, Ekici F, Cetin II, Bilgin L. Heparin infusion to prevent umbilical venous catheter related thrombosis in neonates. Thrombosis Research 2012;130(5):725-8.
293. Uslu S, Ozdemir H, Comert S, Bolat F, Nuhoglu A. The effect of low-dose heparin on maintaining peripherally inserted percutaneous central venous catheters in neonates. Journal of Perinatology 2010;30(12):794-9.
294. Van Rooden CJ, Rosendaal FR, Meinders AE, Van Oostayen JA, Van Der Meer FJ, Huisman MV. The contribution of factor V Leiden and prothrombin G20210A mutation to the risk of central venous catheter-related thrombosis. Haematologica 2004;89(2):201-6.
295. Vegting IL, Tabbers MM, Benninga MA, Wilde JC, Serlie MJ, Tas TA, et al. Prophylactic anticoagulation decreases catheter-related thrombosis and occlusion in children with home parenteral nutrition. JPEN Journal of Parenteral and Enteral Nutrition 2012;36(4):456-62.
296. Venditto M, du Montcel ST, Robert J, Trystam D, Dighiero J, Hue D, et al. Effect of catheter-lock solutions on catheter-related infection and inflammatory syndrome in hemodialysis patients: heparin versus citrate 46% versus heparin/gentamicin. Blood Purification 2010;29(3):268-73.
297. Vercaigne L. Efficacy and safety of an ethanol/sodium citrate locking solution to prevent hemodialysis catheter-related infections: a pilot study. http://clinicaltrials.gov/ct2/show/NCT01394458?term=Efficacy+and+Safety+of+an+Ethanol%2FSodium+Citrate+Locking+Solution%3A+A+Pilot+Study&rank=1 (accessed 6 October 2014) 2011.
298. Verso M, Agnelli G, Bertoglio S, Di Somma FC, Paoletti F, Ageno W, et al. Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. Journal of Clinical Oncology 2005;23(18):4057-62.
299. Verso M, Agnelli G, Kamphuisen PW, Ageno W, Bazzan M, Lazzaro A, et al. Risk factors for upper limb deep vein thrombosis associated with the use of central vein catheter in cancer patients. Internal and Emergency Medicine 2008;3(2):117-22.
300. Vertrees RA, Zwischenberger JB, Woodson LC, Bedell EA, Deyo DJ, Chernin JM. Veno-venous perfusion-induced systemic hyperthermia: case report with perfusion considerations. Perfusion 2001;16(3):243-8.
301. Wan XL, Zeng LN. Heparin added in total nutrient admixture for preventing peripherally inserted central catheter occlusion in neonate: A case report. Chinese Journal of Evidence-Based Medicine 2012;12(10):1275-8.
302. Wang R, Luo O, He L, Li JX, Zhang MG. Preservative-free 0.9% sodium chloride for flushing and locking peripheral intravenous access device: a prospective controlled trial. Journal of Evidence-Based Medicine 2012;5(4):205-8.
303. Warkentin TE, Ling E, Ho A, Sheppard JI. 'Incidental' unfractionated heparin (UFH) vs normal saline (NS) flushes for intraoperative invasive catheters and the frequency of formation of heparin induced thrombocytopenia IgG antibodies (HIT-IgG): A randomized controlled trial. Blood 1998;92(10 Suppl 1 (Pt 2)):91.
304. Wassenaar T, Black J, Kahl B, Schwartz B, Longo W, Mosher D, et al. Acute promyelocytic leukaemia and acquired alpha-2-plasmin inhibitor deficiency: a retrospective look at the use of epsilon-aminocaproic acid (Amicar) in 30 patients. Hematological Oncology 2008;26(4):241-6.
305. Weijmer MC, van den Dorpel MA, Van de Ven PJ, ter Wee PM, van Geelen JA, Groeneveld JO, et al. Randomized, clinical trial comparison of trisodium citrate 30% and heparin as catheter-locking solution in hemodialysis patients. Journal of the American Society of Nephrology 2005;16(9):2769-77.
306. White M, Crawley J, Rennie E, Lewandowski L. Examining the effectiveness of 2 solutions used to flush capped pediatric peripheral intravenous catheters. Journal of Infusion Nursing 2011;34(4):260-70.
307. Whitta RK, Hall KF, Bennetts TM, Welman L, Rawlins P. Comparison of normal or heparinised saline flushing on function of arterial lines. Critical Care and Resuscitation 2006;8(3):205-8.
308. Willicombe MK, Vernon K, Davenport A. Embolic complications from central venous hemodialysis catheters used with hypertonic citrate locking solution. American Journal of Kidney Diseases 2010;55(2):348-51.
309. Winnett G, Nolan J, Miller M, Ashman N. Trisodium citrate 46.7% selectively and safely reduces staphylococcal catheter-related bacteraemia. Nephrology Dialysis Transplantation 2008;23(11):3592-8.
310. Witkovski MC. Continuous or intermittent for keeping arterial catheter in children: a randomized clinical trial. http://clinicaltrials.gov/ct2/show/NCT01097031?term=Continuous+or+Intermittent+for+Keeping+Arterial+Catheter+in+Children%3A+A+Randomized+Clinical+Trial&rank=1 (accessed 6 October 2014) 2010.
311. Wolf J. A double-blind, randomized, placebo-controlled trial of ethanol lock therapy for treatment and secondary prophylaxis of central line associated bloodstream infection (CLABSI) in children and adolescents. http://clinicaltrials.gov/ct2/show/NCT01472965?term=Ethanol+Lock+Therapy+for+Treatment+and+Secondary+Prophylaxis+of+Central+Line-Associated+Bloodstream+Infection&rank=1 (accessed 6 October 2014) 2011.
312. Wolley M, Freeman J, Zoysa DJ, Wei J. Antimicrobial locks in a dialysis unit: reduction in gram negative catheterassociated bloodstream infection without significant impact on rates of S. Aureus infection. Nephrology 2010;15(4):35.
313. Wong FSY, Cheng YL, Chow NY, Cheung ALC, Chau SK, Ngai MS, et al. Effect of 3 different solutions used for locking hemodialysis catheter on systemic coagulation: a randomized study. Hemodialysis International 2009;13(3):403.
314. Wooldridge JB, Jackson JG, Wooldridge JB, Jackson JG. Evaluation of bruises and areas of induration after two techniques of subcutaneous heparin injection. Heart and Lung 1988;17(5):476-82.
315. Worly JM, Fortenberry JD, Hansen I, Chambliss CR, Stockwell J. Deep venous thrombosis in children with diabetic ketoacidosis and femoral central venous catheters. Pediatrics 2004;113(1):e57-e60.
316. Wright A, Hecker J, McDonald G. Effects of low-dose heparin on failure of intravenous infusions in children. Heart & Lung 1995;24(1):79-82.
317. Yevzlin AS, Sanchez RJ, Hiatt JG, Washington MH, Wakeen M, Hofmann RM, et al. Concentrated heparin lock is associated with major bleeding complications after tunneled hemodialysis catheter placement. Seminars in Dialysis 2007;20(4):351-4.
318. Yilmaz KB, Akinci M, Dogan L, Yologlu Z, Atalay C, Kulacoglu H. Central venous catheter-associated thrombosis in the perioperative period: a frequent complication in cancer patients that can be detected early with Doppler examination. Tumori 2010;96(5):690-4.
319. Yon CK, Low CL. Sodium citrate 4% versus heparin as a lock solution in hemodialysis patients with central venous catheters. America Journal of Health-System Pharmacy 2013;70(2):131-6.
320. Young AM, Billingham LJ, Begum G, Kerr DJ, Hughes AI, Rea DW, et al. WARP Collaborative Group, UK. Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial. Lancet 2009;373(9663):567-74.
321. Zacharski LR, Prandoni P, Monreal M. Warfarin versus low-molecular-weight heparin therapy in cancer patients. Oncologist 2005;10(1):72-79.
322. Zhang P, Yuan J, Tan HZ, Lv R, Chen JH. Successful prevention of cuffed hemodialysis catheter-related infection using an antibiotic lock technique by strictly catheter-restricted antibiotic lock solution method. Blood Purification 2009;27(2):206-11.
323. Battistelli S, Genovese A, Gori T. Heparin-induced thrombocytopenia in surgical patients. The American Journal of Surgery 2010;199(1):43-51.
324. Bern MM, Lokich JJ, Wallach SR, Bothe A, Benotti PN, Arkin CF, et al. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Annals of Internal Medicine 1990;112(6):423-8.
325. Bishop L. Aftercare and management of central venous access devices. In: Hamilton H, Bodenham A editor(s). Central venous catheters. 1st Edition. Chichester: Wiley & Blackwell, 2009:221-37.
326. Bradford NK, Edwards RM, Chan RJ. Heparin versus 0.9% sodium chloride intermittent flushing for the prevention of occlusion in long term central venous catheters in infants and children. Cochrane Database of Systematic Reviews 2014, Issue 2. [DOI: 10.1002/14651858.CD010996]
327. Burns KE, McLaren A. A critical review of thromboembolic complications associated with central venous catheters. Canadian Journal of Anaesthesia 2008;55(8):532-41.
328. Goode CJ, Titler M, Rakel B, Ones DS, Kleiber C, Small S, et al. A meta-analysis of effects of heparin flush and saline flush: quality and cost implications. Nursing Research 1991;40(6):324-30.
329. Higgins JPT, Thompson SG, Deeks JJ, Altmann DG. Measuring inconsistency in meta-analyses. British Medical Journal 2003;327(7414):557-60.
330. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org. Chichester: Cochrane Handbook for Systematic Reviews of Interventions, 2011.
331. Jacobs BR. Central venous catheter occlusion and thrombosis. Critical Care Clinics 2003;19(3):489-514.
332. Klerk CPW, Smorenburg SM, Büller HR. Thrombosis prophylaxis in patient populations with a central venous catheter. Archives of Internal Medicine 2003;163(16):1913-21.
333. Lee DH, Warkentin TE. Frequency of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A editor(s). Heparin-Induced Thrombocytopenia. 4th Edition. New York: Informa Healthcare, 2007:67-116.
334. Lopez-Briz E, Ruiz-Garcia V. Effectiveness of heparin versus NaCl 0, 9% in central venous catheter flushing. a systematic review [Heparina frente a cloruro sódico 0, 9% para mantener permeables los catéteres venosos centrales. Una revisión sistemática]. Farmacia Hospitalaria 2005;29(4):258-64.
335. López-Briz E, Ruiz Garcia V, Cabello JB, Bort-Marti S, Carbonell Sanchis R, Burls A. Heparin versus 0.9% sodium chloride intermittent flushing for prevention of occlusion in central venous catheters in adults. Cochrane Database of Systematic Reviews 2010, Issue 4. [DOI: 10.1002/14651858.CD008462]
336. Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 2005;106(8):2710-5.
337. McNulty I, Katz E, Kim KY. Thrombocytopenia following heparin flush. Progress in Cardiovascular Nursing 2005;20(4):143-7.
338. McQuay HJ, Moore RA. Using numerical results from systematic reviews in clinical practice. Annals of Internal Medicine 1997;126(9):712-20.
339. Mermel LA. Prevention of intravascular catheter-related infections. Annals of Internal Medicine 2000;132(5):391-402.
340. Merrer J, De Jonghe B, Golliot F, Lefrant JY, Raffy E, Barre E, et al. French Catheter Study Group in Intensive Care. Complications of femoral and subclavian venous catheterization in critically ill patients: a randomized controlled trial. JAMA 2001;286(6):700-7.
341. Mitchell MD, Anderson BJ, Williams K, Umscheid CA. Heparin flushing and other interventions to maintain patency of central venous catheters: a systematic review. Journal of Advanced Nursing 2009;65(10):2007-21.
342. Raad I, Darouiche R, Dupuis J, Abi-Said D, Gabrielli A, Hachem R, et al. Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infections. A randomized, double-blind trial. The Texas Medical Center Catheter Study Group. Annals of Internal Medicine 1997;127(4):267-74.
343. Randolph AG. An evidence-based approach to central venous catheter management to prevent catheter-related infection in critically ill patients. Critical Care Clinics 1998;14(3):411-21.
344. Randolph AG, Cook DJ, Gonzales CA, Andrew M. Benefit of heparin in central venous and pulmonary artery catheters: a meta-analysis of randomized controlled trials. Chest 1998;113(1):165-71.
345. Shah PS, Shah VS. Continuous heparin infusion to prevent thrombosis and catheter occlusion in neonates with peripherally placed percutaneous central venous catheters. Cochrane Database of Systematic Reviews 2008, Issue 2. [DOI: 10.1002/14651858.CD002772.pub3]
346. Smith RN. Central venous catheters. BMJ 2013;347:f6570. [DOI: 10.1136/bmj.f6570]
347. Valerio D, Hussey JK, Smith FW. Central vein thrombosis associated with intravenous feeding - a prospective study. JPEN Journal of Parenteral and Enteral Nutrition 1981;5(3):240-2.
348. Veenstra DL, Saint S, Saha S, Lumley T, Sullivan SD. Efficacy of antiseptic-impregnated central venous catheters in preventing catheter-related bloodstream infection: a meta-analysis. JAMA 1999;281(3):261-7.
349. Verso M, Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. Journal of Clinical Oncology 2003;21(19):3665-75.
350. Warkentin TE. Clinical picture of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A editor(s). Heparin-Induced Thrombocytopenia. 4th Edition. New York: Informa Healthcare, 2007:21-66.